Evidence map›Paper›PMID 25674276›Full record

ReviewInternational journal of clinical and experimental pathology2014

IgG3 subclass-positive primary thymic MALT lymphoma without trisomy 3 and trisomy 18: report of a case and review of literature.

Kei-Ji Sugimoto, Miki Asahina, Asami Shimada, Kunimoto Ichikawa, Mutsumi Wakabayashi, Yasunobu Sekiguchi, Hiroshi Izumi, Yasunori Ota, Norio Komatsu, Masaaki Noguchi

Open access · greenAbstract readCase ReportsReview
In one paragraph

Review in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kei-Ji SugimotoDepartment of Hematology, Juntendo University Urayasu Hospital Chiba, Japan.
Miki AsahinaDepartment of Human Pathology, Juntendo University School of Medicine Tokyo, Japan.
Asami ShimadaDepartment of Hematology, Juntendo University Urayasu Hospital Chiba, Japan.
Kunimoto IchikawaDepartment of Hematology, Juntendo University Urayasu Hospital Chiba, Japan.
Mutsumi WakabayashiDepartment of Hematology, Juntendo University Urayasu Hospital Chiba, Japan.
Yasunobu SekiguchiDepartment of Hematology, Juntendo University Urayasu Hospital Chiba, Japan.
Hiroshi IzumiDepartment of Pathology, Juntendo University Urayasu Hospital Chiba, Japan.
Yasunori OtaDepartment of Pathology, Research Hospital, The Institute of Medical Science, the University of Tokyo Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine Tokyo, Japan.
Masaaki NoguchiDepartment of Hematology, Juntendo University Urayasu Hospital Chiba, Japan.
Juntendo University Urayasu Hospital · JPJuntendo University · JPTokyo Medical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The patient, a 42-year-old man, was diagnosed as having an anterior mediastinal tumor. Examination of the resected tumor showed findings consistent with a primary thymic mucosa-associated lymphoid tissue lymphoma, stage IA. Postoperative (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography demonstrated fluorodeoxyglucose accumulation at the site of tumor excision. This accumulation was interpreted as representing a residual lesion, and the patient was treated with rituximab. The patient has since been in a state of complete remission for about 3 years. Sporadic mucosa-associated lymphoid tissue lymphoma cells that appeared to have a propensity for differentiating into plasma cells in this case were analyzed for IgG and IgG subclass expression by immunohistochemical staining. The mucosa-associated lymphoid tissue lymphoma cells that showed a propensity for differentiating into IgG-positive plasma cells were IgG3-positive and IgG1-, IgG2- and IgG4-negative. An increase in IgG3 or IgG1 expression in immune cells has been previously demonstrated in immune responses to continuous exposure to the same proteins or peptide antigens and most mucosa-associated lymphoid tissue lymphomas show increased IgG3 and/or IgG1 expression. It is consistent with the fact that inflammation due to stimulation by a pathogenic antigen is considered to be etiologically responsible for the development of mucosa-associated lymphoid tissue lymphoma.

Indexed as

TrisomyAdultChromosomes, Human, Pair 18Chromosomes, Human, Pair 3HumansImmunoglobulin GImmunohistochemistryLymphoma, B-Cell, Marginal ZoneMaleMediastinal NeoplasmsPlasma CellsThymus NeoplasmsImmunoglobulin GIgG1IgG3Mucosa-associated lymphoid tissue (MALT) lymphomaparaffin-embedded tissue section-fluorescence in situ hybridization (PS-FISH)thymus

Identifiers

PMID25674276
PMCPMC4313997
OpenAlexW36540793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.